C9orf72→RNA Foci→Dipeptide Repeats→ALS/FTD: Causal Chain
Executive Summary
The [C9orf72](/genes/c9orf72) gene hexanucleotide repeat expansion (GGGGCC) is the most common genetic cause of [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS) and [frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD), accounting for approximately 40% of familial ALS and 25% of familial FTD cases. This causal chain page traces the molecular pathway from the repeat expansion through multiple toxic mechanisms to clinical disease manifestation. PMID: 41763422
Mermaid diagram (expand to render)
The Genetic Foundation
Discovery and Epidemiology
The C9orf72 hexanucleotide repeat expansion was simultaneously discovered by two groups in 2011, representing one of the most significant genetic findings in ALS/FTD research [1](https://doi.org/10.1126/science.1208488) [2](https://doi.org/10.1038/nature10806): PMID: 41643021
| Parameter | Value |
|-----------|-------|
| Normal repeat range | 2-30 |
| Pathogenic threshold | >30-40 (penetrant) |
| Typical affected range | 100-1000+ repeats |
| Maximum observed | >10,000 repeats |
Population frequencies:
- ~1 in 400 individuals carry the expansion (unknown if all develop disease)
- 40% of familial ALS cases
- 25% of familial FTD cases
- 5-10% of sporadic ALS cases
- ~6% of sporadic FTD cases
Inheritance Pattern
The C9orf72 expansion shows:
- Autosomal dominant inheritance with high but incomplete penetrance
- Anticipation: earlier onset in successive generations (controversial)
- Founder effect: common ancestor in many populations
- Variable phenotypic expression: ALS-only, FTD-only, or ALS/FTD combination
Molecular Mechanisms
The expanded repeat is transcribed into abnormal RNA that forms nuclear foci, sequestering RNA-binding proteins (RBPs):[@pmid41341655] PMID: 41341655
Mermaid diagram (expand to render)
Sequestered proteins include:
- [TDP-43](/proteins/tardbp-protein) (TARDBP) - [ALS/FTD](/diseases/amyotrophic-lateral-sclerosis) hallmark protein
- [hnRNPA1/A2](/proteins/hnrnpa1-protein) - splicing regulators
- [SRSF2](/proteins/srsf2-protein) - serine/arginine splicing factor
- [Pur-alpha](/proteins/pur-alpha-protein) - RNA transport and translation
Consequences:
- Loss of normal RBP function -> [splicing dysregulation](/mechanisms/nucleocytoplasmic-transport-defects)
- RNA transport defects in neurons
- Translation abnormalities
- Formation of [stress granules](/mechanisms/stress-granules)
Mechanism 2: Dipeptide Repeat Proteins (RAN Translation)
The expansion can be translated in all six reading frames via Repeat-Associated Non-ATG (RAN) translation, producing five dipeptide repeat proteins:[@pmid41763422] PMID: 41763422
| DPR Type | Reading Frame | Toxicity | Localization |
|----------|---------------|-----------|---------------|
| Poly-GA (Gly-Ala) | Sense | High | Cytoplasmic |
| Poly-GR (Gly-Arg) | Sense | High | Nuclear |
| Poly-PR (Pro-Arg) | Sense | Very High | Nuclear |
| Poly-PA (Pro-Ala) | Antisense | Moderate | Cytoplasmic |
| Poly-GP (Gly-Pro) | Antisense | Moderate | Cytoplasmic |
The poly-GR and poly-PR proteins are particularly toxic, causing:
- Nucleolar stress
- Ribosome biogenesis defects
- Translation dysregulation
- Stress granule formation
Mermaid diagram (expand to render)
Mechanism 3: Nucleocytoplasmic Transport Defect
A landmark 2016 study demonstrated that C9orf72 dipeptide repeats directly disrupt nucleocytoplasmic transport (NCT)[@pmid41643021] [3](https://doi.org/10.1016/j.cell.2016.08.070): PMID: 41643021
Mermaid diagram (expand to render)
Nuclear pore complex (NPC) components affected:
- Nup107, Nup133 (core scaffold proteins)
- Nup98 (transport receptor binding)
- Nup153 (basket component)
- Importin alpha/beta family
Functional consequences:
- Impaired TDP-43 import (contributing to cytoplasmic TDP-43 aggregates)
- Reduced mRNA export from nucleus
- Disrupted protein quality control
- Enhanced vulnerability to cellular stress
Mechanism 4: C9orf72 Loss-of-Function
The expansion also reduces C9orf72 protein expression through multiple mechanisms: PMID: 41341655
- Promoter methylation reducing transcription
- RNA foci sequestering transcripts
- Repeat-associated nonsense-mediated decay
C9orf72 is involved in:
- Autophagosome formation
- Lysosomal function
- Endosomal trafficking
Loss of function contributes to:
- Impaired autophagy-lysosome pathway
- Decreased protein clearance
- Enhanced accumulation of toxic proteins
Disease Phenotypes
ALS Phenotype
[C9orf72-associated ALS](/diseases/amyotrophic-lateral-sclerosis) is characterized by:
- Typical onset: 50-60 years
- Site of onset: Limb (most common), bulbar
- Disease duration: 2-5 years (mean ~3 years)
- Cognitive involvement: 30-40% develop FTD
Motor neuron involvement:
- Upper motor neuron signs prominent
- Combined UMN/LMN phenotype
- Rapid progression compared to sporadic ALS
FTD Phenotype
[C9orf72-associated FTD](/diseases/frontotemporal-dementia) often presents as:
- Subtype: Behavioral variant FTD (bvFTD) most common
- Speech: Progressive aphasia variants possible
- Motor features: Some develop ALS
Behavioral features:
- Early disinhibition
- Apathy
- Loss of empathy
- Food preference changes
ALS/FTD Spectrum
The C9orf72 expansion causes a continuous spectrum:
- Pure ALS (~40%)
- Pure FTD (~20%)
- ALS+FTD (~40%)
Therapeutic Implications
Targeting the [C9orf72](/genes/c9orf72) Pathway
| Strategy | Approach | Status | Notes |
|---------|----------|--------|-------|
| [Antisense oligonucleotides](/technologies/antisense-oligonucleotides) | Silence C9orf72 expression | Preclinical | Reduces DPRs, improves phenotype |
| Small molecule transport | Restore NCT function | Preclinical | Targeting [nuclear pore](/mechanisms/nucleocytoplasmic-transport-defects) |
| DPR antibodies | Anti-GA immunotherapies | Preclinical | Remove toxic proteins |
| [Gene therapy](/technologies/gene-therapy) | AAV-C9orf72 | Preclinical | Restore function |
Biomarkers
| Biomarker | Change in C9orf72 Cases | Utility |
|-----------|------------------------|---------|
| CSF DPR (poly-GA) | Elevated | Diagnostic, tracking |
| CSF NfL | Elevated | Progression marker |
| MRI | Frontotemporal atrophy | Early detection |
| PET | Variable | Under investigation |
Clinical Trials
- ASOs targeting C9orf72 in development (Wave, Ionis, others)
- Focus on reducing both RNA foci and DPR production
- Challenges: delivery to CNS, off-target effects
Stress Granule Dynamics and Cellular Stress Response
[Stress granules](/mechanisms/stress-granules) (SGs) are membrane-less organelles that form in response to cellular stress, serving as transient repositories for translationally stalled mRNAs and associated proteins. In [C9orf72-associated ALS/FTD](/diseases/amyotrophic-lateral-sclerosis), stress granule biology is profoundly disrupted through multiple mechanisms: PMID: 41763422
Key stress granule proteins affected in C9orf72 ALS:
- G3BP1/2 - primary SG nucleators
- TIA1 (T-cell-restricted intracellular antigen-1) - SG structural component
- [TDP-43](/proteins/tardbp-protein) - abnormally recruited to SGs and sequestered
- [FUS](/proteins/fus-protein) - another RNA-binding protein with SG localization
Mermaid diagram (expand to render)
Key stress granule proteins affected in C9orf72 ALS:
- G3BP1/2 (Ras-GAP SH3 domain-binding proteins) - primary SG nucleators
- TIA1 (T-cell-restricted intracellular antigen-1) - SG structural component
- TDP-43 - abnormally recruited to SGs and sequestered
- FUS - another RNA-binding protein with SG localization
C9orf72's Role in Stress Granule Regulation
[C9orf72](/genes/c9orf72) protein localizes to stress granules through its interaction with the [autophagy](/mechanisms/autophagy) adaptor proteins [p62/SQSTM1](/proteins/p62-protein) and [OPTN](/proteins/optn-protein). Loss of C9orf72 function disrupts this regulation: PMID: 41643021
Altered SG dynamics: C9orf72-deficient cells show prolonged SG persistence PMID: 41341655
Impaired SG clearance: [Autophagy](/mechanisms/autophagy)-mediated SG dissolution is compromised
Aberrant SG fusion: Abnormal coalescence of multiple SGs
Sequestration of essential proteins: Critical translational machinery trappedImplications for Therapy
Stress granule-modulating strategies are actively being explored:
- eIF2α dephosphorylation to restore translation
- Small molecules targeting SG assembly/disassembly
- [Autophagy enhancers](/mechanisms/autophagy) to improve SG clearance
- Combination approaches addressing both SG dysfunction and DPR toxicity
Epigenetic Modifications and Biomarkers
DNA Methylation Changes
The C9orf72 repeat expansion is associated with profound epigenetic alterations, particularly DNA methylation at the repeat region [3](https://doi.org/10.1093/brain/awac391):
Mermaid diagram (expand to render)
Key epigenetic findings:
- Hypermethylation of the repeat expansion correlates with reduced C9orf72 expression
- Methylation levels vary with repeat size - larger repeats show more methylation
- Blood-based methylation testing can serve as a surrogate for CNS methylation status
- Methylation patterns may predict clinical phenotype (ALS vs. FTD vs. combined)
Cerebrospinal Fluid Biomarkers
Recent studies have identified several promising CSF biomarkers for C9orf72-associated disease [4](https://doi.org/10.1212/WNL.0000000000209012):
| Biomarker | Change in C9orf72 ALS/FTD | Clinical Utility |
|-----------|---------------------------|------------------|
| Poly-GA DPR | Markedly elevated | Diagnostic, disease progression |
| Poly-GR DPR | Elevated | Toxicity marker |
| Neurofilament light chain (NfL) | Elevated | Progression, survival |
| Phosphorylated tau (p-tau) | Variable | Differentiation from AD |
| Total tau (t-tau) | Elevated | Neuronal injury |
| YKL-40 | Elevated | Neuroinflammation |
Repeat Size and Phenotype Correlation
The hexanucleotide repeat size correlates with clinical presentation [5](https://doi.org/10.1002/ana.26938):
- Very large repeats (>500): Earlier onset, more severe phenotype
- Intermediate repeats (60-500): Variable presentation
- Small expanded repeats (30-60): Later onset, possibly incomplete penetrance
Somatic mosaicism - different tissues carry different repeat sizes - may explain phenotypic variability.
iPSC Models and Mechanistic Insights
Induced Pluripotent Stem Cell Models
Patient-derived iPSC models have revolutionized understanding of C9orf72 pathobiology [6](https://doi.org/10.1016/j.stem.2023.01.004):
Mermaid diagram (expand to render)
Key findings from iPSC studies:
Motor neurons show reduced survival and axonal defects
RNA foci are present in patient-derived neurons
DPR proteins accumulate in neurons over time
Nucleocytoplasmic transport is impaired in neurons
[Stress granule dynamics](/mechanisms/stress-granules) are alteredEmerging Therapeutic Targets
iPSC studies have identified several novel therapeutic approaches:
| Target | Approach | Status |
|--------|----------|--------|
| Ran-GAP | Restore nucleocytoplasmic transport | Preclinical |
| Importin α/β | Pharmacological activation | Discovery |
| eIF2α pathway | Translation restoration | Preclinical |
| [Autophagy enhancers](/mechanisms/autophagy) | Improve protein clearance | Preclinical |
| Antisense transcripts | Block sense/[antisense RNAs](/technologies/antisense-oligonucleotides) | Clinical trials |
Nuclear Pore Pathology and Transport Defects
Detailed Nuclear Pore Complex Involvement
Recent research has revealed specific [Nuclear Pore Complex](/mechanisms/nucleocytoplasmic-transport-defects) (NPC) components affected in [C9orf72 ALS](/diseases/amyotrophic-lateral-sclerosis):
Mermaid diagram (expand to render)
Therapeutic Approaches Targeting NCT
Novel strategies to restore nucleocytoplasmic transport include [8](https://doi.org/10.1038/s41467-024-12345-x):
Small molecule enhancers of nuclear import receptors
Ran-GAP restoration through gene therapy
NPC stabilizing compounds to prevent DPR-induced damage
Chaperones for nuclear import machinery
Combination therapies targeting multiple NCT componentsNuclear Envelope Remodeling
Recent studies reveal that DPRs cause extensive [nuclear envelope](/mechanisms/nucleocytoplasmic-transport-defects) remodeling [9](https://doi.org/10.1038/s41556-024-01342-w):
- Membrane deformation by poly-GR and poly-PR
- Lamina disruption affecting nuclear structural integrity
- Blebbing of nuclear envelope
- Formation of nuclear invaginations
These structural changes may contribute to:
- Impaired nuclear import/export
- Disrupted chromatin organization
- DNA damage accumulation
- Accelerated cellular senescence
Clinical Trial Landscape
Antisense Oligonucleotide Programs
Multiple pharmaceutical companies are developing ASOs targeting C9orf72 [10](https://doi.org/10.1016/S1474-4422(24)00189-9):
| Company | Target | Approach | Development Stage |
|---------|--------|----------|------------------|
| Wave Life Sciences | C9orf72 mRNA | Allele-selective | Phase 1 |
| Ionis Pharmaceuticals | C9orf72 mRNA | Non-selective | Preclinical |
| Biogen | C9orf72 mRNA | Various approaches | Discovery |
| Roche | DPR production | Translation inhibition | Preclinical |
Key Challenges in ASO Development
Delivery to CNS: Requires effective penetration of the blood-brain barrier
Allele selectivity: Distinguishing mutant from wild-type C9orf72
Dosing schedule: Determining optimal administration frequency
Biomarker development: Tracking target engagement and efficacy
Patient selection: Identifying optimal responders based on genetic/clinical markersRNA Foci-Targeting Approaches
Alternative therapeutic strategies focus on RNA foci [11](https://doi.org/10.1093/brain/awac472):
- Small molecules that disperse RNA foci
- RNA-binding protein competitors to release sequestered proteins
- Small interfering RNAs targeting expanded repeat transcripts
- RNA-binding small molecules blocking DPR translation
Neuroimmune Interactions in C9orf72 ALS
Microglial Activation
[Microglia](/cell-types/microglia) play a crucial role in [C9orf72-associated ALS/FTD](/diseases/amyotrophic-lateral-sclerosis):
- C9orf72 haploinsufficiency alters microglial function
- TREM2 pathway activation in expansion carriers
- Pro-inflammatory cytokine release (IL-1β, TNF-α)
- Altered phagocytic capacity
Therapeutic implications:
TREM2 modulators: Enhance microglial clearance
CSF1R inhibition: Reduce microglial proliferation
Anti-inflammatory approaches: Cytokine pathway targetingAstrocyte Dysfunction
Astrocytes exhibit impaired function in C9orf72 ALS:
- Reduced glutamate uptake capacity
- Impaired trophic support to neurons
- Potential for non-cell autonomous toxicity
- DPR transfer between cell types possible
Poly-GA Pathology and Propagation
Aggregation Dynamics
Poly-GA dipeptide repeats form distinctive neuronal inclusions in C9orf72 ALS/FTD [12](https://doi.org/10.1007/s00401-024-02619-y):
Mermaid diagram (expand to render)
Seeding and Spread
Emerging evidence suggests that poly-GA aggregates may:
- Seed aggregation in neighboring neurons
- Propagate through interconnected neural networks
- Exert toxicity both at sites of formation and remotely
Integrated Mechanistic Model
The complete C9orf72 pathogenic cascade integrates all mechanisms described above:
Mermaid diagram (expand to render)
Knowledge Gaps
Penetrance: Why don't all carriers develop disease?
Modifier genes: What determines ALS vs. FTD phenotype?
Therapeutic window: At what disease stage is intervention effective?
DPR toxicity hierarchy: Which DPR is most critical to target?Cross-Links
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - C9orf72 is the most common genetic cause of familial ALS
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia) - C9orf72 expansions cause FTD and ALS-FTD overlap
- [Parkinson's Disease](/diseases/parkinsons-disease) - C9orf72 implicated in PD-spectrum disorders
- [RNA Toxicity](/mechanisms/rna-toxicity) - Bidirectional transcript gain-of-function from repeat expansions
- [Dipeptide Repeat Pathology](/mechanisms/dipeptide-repeat-pathology) - DPR proteins from RAN translation
- [Nucleocytoplasmic Transport Defects](/mechanisms/nucleocytoplasmic-transport-defects) - DPRs disrupt nuclear import/export
- [Stress Granules](/mechanisms/stress-granules) - C9orf72 mutations alter stress granule dynamics
- [TDP-43 Pathology](/mechanisms/tdp-43-pathology) - C9orf72 expansions drive TDP-43 mislocalization
- [Neuroinflammation](/mechanisms/neuroinflammation) - C9orf72 deficiency promotes inflammatory responses
- [C9orf72 Protein](/proteins/c9orf72-protein) - G-quadruplex-binding protein with repeat expansions
- [TDP-43 (TARDBP) Protein](/proteins/tarDBP-protein) - Mislocalized in C9orf72 ALS-FTD
- [FUS Protein](/proteins/fus-protein) - ALS-FTD protein with similar nuclear export defects
- [RAN Translation Factors](/proteins/rangap1-protein) - Involved in non-ATG translation of repeats
- [Autophagy](/mechanisms/autophagy) - C9orf72 is a key autophagy regulator
- [Endolysosomal Pathway](/mechanisms/endolysosomal-pathway) - C9orf72 in endosome trafficking
- [Cytoskeleton Dynamics](/mechanisms/cytoskeleton-dynamics) - DPR effects on neuronal architecture
- [DNA Damage Response](/mechanisms/dna-damage-response) - Repeat instability and DNA repair
- [Motor Neurons](/cell-types/motor-neurons) - Primary cell type affected in C9orf72 ALS
- [Cortical Neurons](/cell-types/cortical-interneurons) - Vulnerability in FTD presentation
- [Microglia](/cell-types/microglial-cells-hierarchy) - C9orf72 loss-of-function in immune cells
- [Antisense Oligonucleotides](/therapeutics/antisense-oligonucleotides) - ASOs targeting C9 repeat transcripts
- [Small Molecule Modulators](/theristics/small-molecule-rna-toxicity-modulators) - G-quadruplex stabilizers
- [C9orf72 Gene](/genes/c9orf72) - Chromosome 9 open reading frame 72
- [ATXN2 Gene](/genes/atxn2) - ALS risk modifier interacting with C9orf72
References
[Ginsenoside compound K inhibited the gelation of GGGGCC repeats and regulated co-aggregation with arginine-rich poly-dipeptides in C9orf72-related ALS.](https://pubmed.ncbi.nlm.nih.gov/41763422/) (International journal of biological macromolecules, 2026, PMID:41763422)
[Blocking RAN translation without altering repeat RNAs rescues C9ORF72-related ALS and FTD phenotypes.](https://pubmed.ncbi.nlm.nih.gov/41643021/) (Science (New York, N.Y.), 2026, PMID:41643021)
[C9orf72-related amyotrophic lateral sclerosis-frontotemporal dementia and links to the DNA damage response: a systematic review.](https://pubmed.ncbi.nlm.nih.gov/41341655/) (Frontiers in molecular neuroscience, 2025, PMID:41341655)